# Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma

> **NCT03361319** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Royal Marsden NHS Foundation Trust**

## Conditions studied

- NSCLC, Recurrent
- Adenocarcinoma of Lung

## Interventions

- **DRUG:** Vargatef
- **DRUG:** Abraxane
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT03361319
- **Lead sponsor:** Royal Marsden NHS Foundation Trust
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2020-07
- **Primary completion:** 2023-07
- **Final completion:** 2023-07
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Withdrawal of financial support from funder
- **Last updated:** 2020-11-24

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03361319

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03361319, "Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT03361319. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*